Wall Street Zen upgraded shares of FocalTherics (NASDAQ:FOCL – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.
A number of other equities analysts have also recently weighed in on FOCL. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday, August 25th. Piper Sandler restated a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a report on Friday, August 14th. Mizuho assumed coverage on shares of FocalTherics in a research note on Friday, July 17th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.67.
Check Out Our Latest Report on FocalTherics
FocalTherics Price Performance
FOCL opened at $3.52 on Friday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 1.38. The stock’s fifty day moving average is $4.21. FocalTherics has a fifty-two week low of $1.82 and a fifty-two week high of $6.40.
FocalTherics (NASDAQ:FOCL – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. The business had revenue of $9.83 million for the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. As a group, equities analysts expect that FocalTherics will post -0.82 EPS for the current year.
Insider Activity at FocalTherics
In other FocalTherics news, Director Joshua Levine bought 10,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the transaction, the director directly owned 45,000 shares in the company, valued at approximately $213,750. This represents a 28.57% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David R. Horn bought 10,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, with a total value of $47,500.00. Following the transaction, the director owned 10,000 shares of the company’s stock, valued at $47,500. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 116,000 shares of company stock worth $551,000. Insiders own 10.10% of the company’s stock.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in FocalTherics stock. Rock Springs Capital Management LP boosted its holdings in shares of FocalTherics (NASDAQ:FOCL – Free Report) by 7.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,378,000 shares of the company’s stock after acquiring an additional 91,500 shares during the quarter. Rock Springs Capital Management LP owned 3.68% of FocalTherics worth $5,126,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 62.74% of the company’s stock.
About FocalTherics
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
Read More
- Five stocks we like better than FocalTherics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for FocalTherics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FocalTherics and related companies with MarketBeat.com's FREE daily email newsletter.
